What type of medicine is LARTRUVO?
LARTRUVO is a monoclonal antibody, which is different from a traditional chemotherapy.
Monoclonal antibodies are proteins made in the laboratory and can be used to treat some cancers. They bind to substances in the body, including both cancer and healthy cells, and can block signals that tell tumors to grow.
LARTRUVO is given with a chemotherapy called doxorubicinDoxorubicin: A common cancer chemotherapy that also goes under the trade name Adriamycin®.
Adriamycin is a registered trademark of Pharmacia & Upjohn S.P.A., which is an essential part of your treatment plan. Your doctor will start treatment with LARTRUVO and doxorubicin, and may adjust the medicines in your treatment plan over time.
With LARTRUVO and doxorubicin, your treatment unites an innovative therapy with an established cancer medicine.
How does LARTRUVO work?
Tumors can send signals throughout the body that tell cells to grow and divide. LARTRUVO works to block certain types of signals and may help slow down cancer growth.
As a monoclonal antibody, LARTRUVO can bind to healthy cells in addition to cancer cells, which may lead to serious side effects.
Does LARTRUVO work in my subtype?
LARTRUVO was studied in many different subtypes. Talk to your healthcare team if you have questions regarding your specific subtype.
Why is LARTRUVO right for me?
LARTRUVO has been shown to be effective for adult patients with STS when used with doxorubicin. You are taking LARTRUVO because you and your healthcare team believe it is the right choice for you.